Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.
Keep your PROTAC projects moving forward with in-solution and mass-independent measurements, data that agree with the latest fit models for three-component systems, and flexibility to succeed in characterizing interactions that include covalent binders.
Have a question about Dianthus?
Contact SpecialistSee more related content
Use this downloadable list of 2023 Targeted Protein Degradation conferences to choose which one(s) to attend. Learn when and where they’ll happen, who’ll be there, and the main focus.
8 Targeted Protein Degradation conferences in 2023 you won’t want to miss
2023 is expected to be a year of big announcements in the targeted protein degradation (TPD) therapeutics space. With more than 20 degraders in clinical trials, many decisions are coming. The race...
37:25Put your challenging affinity screening campaigns back on track — after you’ve tried everything else
When you’re entrusted with developing therapeutics for challenging or undruggable targets, it’s a struggle to characterize molecular interactions. And it’s not for lack of effort or expertise — SPR an
59:35Bifunctional degrader molecules (aka PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases, forming a ternary complex that enables ubiquitination and degradation of the target
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
Protein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
9 Targeted Protein Degradation conferences you don’t want to miss in 2022
Update: See which 2023 conferences you should watch for With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on...
For protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
Are you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
6 protein degradation conferences in 2021 you can’t afford to miss
Update: See what 2022 conferences you should watch for Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation...
17:10There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
What are PROTACs: the game-changing modality that promises to tackle undruggable proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...